Table. Demographic and Treatment Characteristics by HSD3B1 Genotypea.
| Characteristic | Patients, No.(%) | P Valueb | ||
|---|---|---|---|---|
| Homozygous Wild-type (n = 97) |
Heterozygous (n = 96) |
Homozygous Variant (n = 20) |
||
| Age at ADT initiation, median (IQR), y | 69 (63-74) | 72 (65-78) | 69 (65-77) | .03 |
| Clinical T stage at diagnosis | .73 | |||
| T1 | 48 (50) | 49 (51) | 10 (50) | |
| T2 | 24 (25) | 17 (18) | 2 (10) | |
| T3-T4 | 4 (4) | 3 (3) | 1 (5) | |
| Tx | 8 (8) | 12 (13) | 2 (10) | |
| Unknown | 13 (13) | 15 (16) | 5 (25) | |
| Clinical N stage at diagnosis | .76 | |||
| N0 | 37 (38) | 38 (40) | 7 (35) | |
| Nx | 47 (48) | 43 (45) | 8 (40) | |
| Unknown | 13 (13) | 15 (16) | 5 (25) | |
| Biopsy Gleason score | .43 | |||
| ≤6 | 29 (30) | 20 (21) | 2 (10) | |
| 7 | 33 (34) | 33 (34) | 10 (50) | |
| 8-10 | 28 (29) | 32 (33) | 6 (30) | |
| Unknown | 7 (7) | 11 (12) | 2 (10) | |
| ADT as part of local therapy | .84 | |||
| No | 49 (51) | 50 (52) | 9 (45) | |
| Yes | 48 (49) | 46 (48) | 11 (55) | |
| Year of ADT initiation | .66 | |||
| 1996-2000 | 25 (26) | 25 (26) | 8 (40) | |
| 2001-2005 | 36 (37) | 31 (32) | 4 (20) | |
| 2006-2010 | 31 (32) | 32 (33) | 6 (30) | |
| 2011-2013 | 5 (5) | 8 (8) | 2 (10) | |
| ADT schedule | .93 | |||
| Continuous | 63 (65) | 62 (65) | 12 (60) | |
| Intermittent | 34 (35) | 34 (35) | 8 (40) | |
| Received an antiandrogen during ADT | >.99 | |||
| No | 43 (44) | 42 (44) | 9 (45) | |
| Yes | 54 (56) | 54 (56) | 11 (55) | |
| PSA at ADT, median (IQR), ng/mL | 8.7 (4.6-18) | 11.4 (6.4-19) | 13.6 (6.0-27) | .13 |
| Follow-up after ADT initiation, median (IQR), y | 6.4 (4.1-10.9) | 8.3 (4.1-13.0) | 7.9 (5.9-13.6) | .56 |
Abbreviations: ADT, androgen-deprivation therapy; IQR, interquartile range; PSA, prostate-specific antigen.
a
Data are presented as number (percentage) of patients unless otherwise indicated.
b
Kruskal-Wallis test for continuous variables or Fisher exact test for categorical variables.